How do I ensure my biomarker discovery work with multi-omics analytics platforms is compliant?

To ensure biomarker discovery work using multi-omics analytics platforms is compliant, treat compliance as a design requirement across the entire workflow—not just a final check. The exact obligations depend on your use case, geography, and whether work is research-only or intended for clinical/diagnostic use.

1) Identify which regulations apply

Start by classifying the activity:

• Research use only (RUO) vs clinical/diagnostic development
• Human subjects research involving identifiable or coded data
• Regulated biomarker claims or companion diagnostic work
• Cross-border data transfer involving patient omics data

Common frameworks may include:

• GDPR / UK GDPR for EU/UK personal data
• HIPAA in the US for protected health information
• 21 CFR Part 11 for electronic records/signatures
• CLIA/CAP if producing or validating clinical lab results
• FDA / EMA / local regulatory rules for diagnostics and claims
• Institutional IRB/ethics committee requirements

2) Define intended use and data scope

Document:

• The scientific objective
• Whether outputs are exploratory or intended for clinical decision-making
• Data types used: genomics, transcriptomics, proteomics, metabolomics, imaging, clinical metadata
• Whether the data are identifiable, coded, or de-identified
• Who will access the data and where it will be processed

This determines whether consent, ethics approval, data processing agreements, or validation requirements are needed.

3) Put governance and documentation in place

Maintain a compliance folder with:

• Protocol and analysis plan
• IRB/ethics approvals
• Informed consent language and permitted uses
• Data processing agreements / BAAs / vendor contracts
• Data retention and deletion policy
• SOPs for data handling, QC, analysis, and version control
• Risk assessments and DPIAs where required
• Audit trails for all major analysis steps

4) Manage consent and lawful basis carefully

For human omics data, ensure:

• Consent covers secondary use, multi-omics integration, and data sharing if applicable
• Re-consent or waiver is obtained when new uses go beyond original consent
• Withdrawal procedures are defined
• The lawful basis for processing is documented under applicable privacy law

5) Apply privacy and security controls

Use strong technical and organizational safeguards:

• De-identify or pseudonymize data where possible
• Minimize data collection to what is needed
• Role-based access control and least privilege
• Encryption in transit and at rest
• Secure key management
• Multi-factor authentication
• Segregated environments for development/test/production
• Logging and monitoring of access and exports
• Secure data sharing methods and approved transfer mechanisms

6) Validate the platform and analyses

If the platform supports regulated or decision-relevant work:

• Validate data ingestion, transformation, normalization, and statistical workflows
• Lock analysis versions for reproducibility
• Document software versions, reference databases, and parameter settings
• Test for correctness, completeness, and traceability
• Confirm any AI/ML models are appropriate for intended use and monitored for drift/bias

For clinical contexts, also establish:

• Analytical validity
• Clinical validity
• Clinical utility, where relevant

7) Control vendors and cloud services

For third-party analytics platforms:

• Review security certifications and audits (e.g., ISO 27001, SOC 2)
• Ensure contracts include confidentiality, breach notification, subprocessor controls, and deletion terms
• Confirm data residency and transfer mechanisms
• Check whether the vendor claims the platform is RUO only
• Determine whether they can support regulated workflows and audit requirements

8) Use good scientific and ethical practices

• Predefine endpoints and avoid p-hacking
• Track batch effects, confounders, and missingness
• Ensure representative datasets to reduce bias
• Validate findings in independent cohorts
• Avoid overstating biomarker claims beyond the evidence

9) Prepare for audits and inspections

Be ready to show:

• Who did what, when, and with what version of the pipeline
• Evidence of approvals and permissions
• Data lineage and provenance
• QC results and deviation handling
• Training records for staff
• Incident and corrective-action records

10) Involve the right experts early

Work with:

• Regulatory affairs
• Privacy counsel / DPO
• IRB/ethics specialists
• Information security
• Quality assurance
• Clinical laboratory leadership, if applicable

---

Practical compliance checklist

Before running analyses, confirm:

• Intended use is documented
• Ethics/IRB approval is in place
• Consent covers the planned use
• Data sharing and transfer terms are approved
• Security controls are implemented
• Vendor contracts are signed and reviewed
• Analysis pipeline is version-controlled and validated
• Audit logs are enabled
• Retention/deletion rules are defined
• Biomarker claims are reviewed by regulatory/legal experts

If you tell me your country/region, whether this is research vs clinical, and whether you’re using cloud/SaaS or on-prem, I can give you a more specific compliance roadmap.